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Abstract   
 
Introduction: Colon cancer is one of the major human malignancies worldwide, 
and much effort has been applied to understand the process of colon 
carcinogenesis, as well as the role of potential treatments and co-therapeutical 
agents against it. A growing body of evidence suggests that the use of 
fluoxetine (FLX), an antidepressant belonging to the selective serotonin 
reuptake inhibitors (SSRIs), may be associated with a reduced colon cancer 
risk. However, controversial opinions have been published and an identification 
of the mechanisms of the activity of FLX on colon cells would help in the 
clarification of this controversy. Objectives: Using several in vitro and in vivo-
based methods and analyses, we aimed to verify whether FLX has antioxidant, 
pro-oxidant or DNA-damaging potential in standard toxicological assays; to 
check whether and how FLX could prevent and reduce colon preneoplastic 
lesions; to ascertain whether FLX has any oncostatic potential against colon 
tumors; and, to investigate whether FLX activity could be comparable with a 
known and current applied chemotherapeutic agent against colon cancer. 
Results: FLX did not have any antioxidant potential in our experiments. 
Although it did not induce reactive oxygen species (ROS) generation or DNA-
damage in fibroblast and colon tumor cell lines, FLX reduced dysplasia and 
proliferation in two different carcinogen models. Further, a significant decrease 
in colon stromal reactivity and angiogenesis was found in both carcinogen-
induced preneoplasia models. In a xenograft model of colon cancer, FLX shrank 
tumors, reduced tumor proliferation, arrested cancer cells at the G0/G1 cell-cycle 
phase, and took ROS generation under control. Such effects were detected 
together with an intracellular acidification and loss of mitochondrial membrane 
potential in FLX-treated cells. Modulating mitochondrial respiratory chain, HIF-1 
expression and Akt/mTOR signaling pathway, FLX was found to reduce colon 
tumors similar to the widely used chemotherapeutic agent 5-Fluoracil activity. 
Conclusion: Our collective data suggest that FLX is a remarkable 
chemopreventive and oncostatic agent against colon preneoplastic lesions and 
tumors, acting without DNA-damage or ROS generation.               
11 
 
Zusammenfassung  
 
Einleitung: Darmkrebs ist eine der wichtigsten menschlichen Tumorarten 
weltweit und viel Aufwand wurde unternommen, um den Prozess der 
Colonkarzinogenese, sowie die Rolle der möglichen Behandlungen und Co-
therapeutische Mittel zu verstehen. Eine wachsende Zahl von Hinweisen 
deuted darauf hin, dass die Verwendung von Fluoxetin (FLX), einem 
Antidepressivum aus der Klasse der selektiven Serotonin-
Wiederaufnahmehemmer (SSRIs), mit einem reduzierten Dickdarmkrebs-Risiko 
verbunden sein kann. Allerdings sind auch kontroverse Meinungen 
veröffentlicht worden und eine Identifizierung der Mechanismen der Aktivität 
von FLX auf Darmzellen würde bei der Klärung dieser Kontroverse helfen. 
Ziele: Mit in vitro-und in vivo-Methoden wollten wir prüfen, ob FLX 
antioxidatives, prooxidatives oder DNA-schädigendes Potential in Standard-
toxikologischen Untersuchungen hat; des weiteren sollte analysiert werden, ob 
und wie FLX präneoplastischen Läsionen verhindern und reduzieren kann, 
sowie ob FLX onkostatisches Potenzial gegen Darmtumoren hat. Letzteres 
sollte im direkten Vergleich mit dem etablierten Chemotherapeutikum 5-
Fluoruracil untersucht werden. Ergebnisse: FLX zeigte keine direkte 
antioxidative Kapazität in unseren Testsystemen. Obwohl es keine Bildung 
reaktiver Sauerstoffspecies (ROS) und keine Induktion von DNA-Schaden in 
Fibroblasten und Kolon Tumorzellinien verursachte, reduzierte FLX Dysplasien 
und Proliferation in zwei verschiedenen Kanzerogen-Modellen in vivo. Ferner 
wurde eine signifikante Abnahme der Reaktivität der Stromazellen und von 
Angiogenese in beiden Karzinogen-induzierten Präneoplasie-Modellen 
gefunden. In einem Xenograft Modell des Kolonkarzinoms brachte FLX die 
Tumoren durch verringerte Proliferation zum Schrumpfen. In vitro wurde in den 
entsprechenden Zellinien eine Anreicherung der Zellen in der Ga0/G1 
Zellzyklus-Phase, eine Reduktion Hypoxie-verursachter ROS-Bildung, 
intrazelluläre Ansäuerung und Velust des mitochondrialen Membranpotentials 
nach FLX-Behandlung gefunden. Weitere Aktivitäten waren auf die 
mitochondriale Atmungskette, HIF-1 Expression und den Akt/mTOR-Sinalweg 
zu beobachten. Die Reduktion der Kolontumoren war der mit 5-Fluoruracil 
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erzielten vergleichbar. Schlussfolgerung: Unsere Daten deuten darauf hin, 
dass FLX eine bemerkenswerte chemopräventive und onkostatischen Aktivität 
gegen präneoplastische Läsionen und Tumore im Darm aufweist, die ohne 
Induktion von DNA-Schäden ROS stattfindet. 
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1 Introduction 
1.1 Fluoxetine  
Fluoxetine (FLX) is a selective serotonin reuptake inhibitor (SSRI), and 
was discovered by a research group from the Eli Lilly Company in 1974  [1]. It is 
a lipophilic weak base administered orally yielding a direct contact with epithelia 
from the gastrointestinal tract. Then, FLX is absorbed and induces an increase 
in serotonin (5-HT) levels by blocking the L-monoamine oxidases (MAO) and 
serotonin reuptake transporters (SERT). A concentration plateau ranging from 
10 to 30 µM was reported in human brain tissue [2-4] 
In 1978, FLX was approved for the treatment of patients with 
depression, anxiety and insomnia, becoming worldwide known as Prozac [5-6]. 
It exhibits higher safety and less side effects than other antidepressants [3,5-7].  
1.2 Fluoxetine and oxidative stress generation  
FLX has been found to act upon the cellular oxidative stress (OS) 
machinery [8-19]. For example, FLX treatment was detected to decrease serum 
malondialdehyde (MDA), superoxide dismutase (SOD), and ascorbic acid levels 
in patients with major depression [8]. In stressed rats, FLX treatment reduced 
MDA and carbonyl levels, whilst it enhanced SOD, catalase (CAT),   glutathione 
S-transferase (GST), glutathione reductase (GR) and glutathione (GSH) 
contents [9-10]. FLX-induced neuroprotective effects were observed in rats 
exposed to  lipopolysaccharide (LPS), since it decreased the translocation of 
p67 protein and reactive oxygen species (ROS) generation suppressing the 
activation of reduced-nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, and inducible nitric oxide synthase (iNOS) [11]. An analysis of blood 
samples from stressed mice showed that FLX reduced ROS generation 
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promoting the activity of SOD, GSH, and CAT in leucocytes [12]. In brain tissue 
of tumor-bearing mice it was found that FLX supported SOD activity [13]. 
Moreover, FLX was shown to reduce ROS generation reversing the melanoma-
induced tissue oxidation in mice [14]. 
On the other hand, FLX was reported to block voltage-gated ion 
channels, as observed by calcium (Ca2+) extracellular influx and its release from 
intracellular stores, which inhibits adenosine-5'-triphosphate (ATP)-induced 
inward currents [15]. Data from Burkitt lymphoma cells revealed that FLX 
stimulated Ca2+ flux, while it reduced the B-cell lymphoma 2 (bcl-2) expression, 
and mitochondrial membrane potential (ΔΨm) increasing deoxyribonucleic acid 
(DNA) fragmentation and apoptosis [16-17]. In human ovarian cancer cell lines, 
FLX induced ROS generation and apoptosis increasing mitochondrial bcl-2-
associated X protein (Bax), cytochrome c release, caspase-3 activation and p53 
expression levels, whilst it also reduced ΔΨm, BH3 interacting-domain death 
agonist (Bid) and bcl-2 levels [18]. Similar results were found in human 
neuroblastomas [19] 
1.3 Fluoxetine and tumors  
In 1982, Tutton and Barkla first reported that FLX has a great potential 
against colon tumors [20]. However, ten years later, Brandes and colleagues 
showed that 40% of mice subjected to FLX-treatment for 5 days developed 
fibrosarcoma, while 95% of rats had breast cancer after 15-weeks [21]. Volpe 
and colleagues did not support these previous findings regarding the stimulatory 
effects of FLX treatment upon breast cancer [22]. Jia et al showed that FLX did 
not affect the growth of pancreatic tumors [23]. Moreover, FLX was shown to 
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reduce lymphoma growth modulating the T-cell-mediated immunity reaction 
through a 5-HT-dependent activity [7]. 
Coogan et al reported that patients subjected to regular FLX treatment 
had a 45% decrease in colon cancer risk [24]. These findings were recently 
supported by data from another research group [25]. Indeed, studies with 
animals also support this idea of FLX reducing colon cancer [5,26]. From cell 
culture experiments, FLX was reported not only to inhibit the multidrug 
resistance and increase the intracellular doxorubicin concentration [27], but also 
to induce an almost exclusive nuclear distribution of this chemotherapeutic drug 
[28]. 
1.4 Incidence of colon tumors 
The American Cancer Society estimates the number of new cases and 
expected deaths for cancer in the United States of America (USA) every year 
[29]. A projection of 1.5 million cases and 569,490 deaths of cancer was 
expected in 2010. It ranked colon cancer as the third most common cancer in 
the country, with almost 50,000 deaths per year [29-30]. In 2012, colon cancer 
was found as the second major malignancy among males, and the third among 
females. It means that the number of diagnosed people reached over 1.2 million 
in the USA, and that 143,460 more new patients will be still diagnosed with 
colon cancer this year [31].   
Survival has increased during the 5 years post-diagnosis in those 
150,000 new cases of colon cancer per  year in the USA [30]. Jemal et al have 
nevertheless projected a 60% increase for new cancer diagnosed cases in 
developing countries until 2030 [32]. It highlights colon cancer as one of the 
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major human malignancies worldwide, and a great challenge for cancer therapy 
[33-35]. 
1.4.1 Adenoma-carcinoma sequence model  
The most well accepted theory about colon carcinogenesis was proposed 
by Fearon and Volgestein. It became known as the adenoma-carcinoma 
sequence model [36]. This theory was mainly based on Foulds’s model, where 
he proposed that most tumors develop throughout a multi-stepped sequence of 
changes [37].  This means that during a progressive process genetic and 
epigenetic mutations in tumor suppressor genes and oncogenes are cumulating 
[38-39]. The tumor initiation is a relatively fast step, since mutations in one or 
two gatekeeper genes abrogate tissue homeostasis by disrupting the regular 
cell turnover [40-41]. Mutated cells seem to automatically undergo clonal 
outgrowth or promotional stage after being stimulated with endogenous or 
exogenous factors [40]. All these steps together can take over decades until the 
full completion of the tumor, since it requires the expansion of mutated cell 
clones, formation of preneoplastic lesions, tumor growth, invasion, and finally 
metastasis [42-44].  
1.4.1  Colon preneoplastic lesions, aberrant crypt foci, or dysplasia 
Understanding the theory of carcinogenic multi-step sequences of 
changes [37] and the adenoma-carcinoma sequence model [36], researchers 
had to find early lesions and transitional stages preceding tumors [36-37,45-46]. 
This means that the concept of first genetic changes (mutations and deletions) 
inducing tumors had to be translated to detectable histological modifications 
[46].    
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Bird therefore identified preneoplastic lesions in the colon of carcinogen 
treated rodents, and named those as aberrant dysplastic crypts [45]. To clarify 
this concept, Bird and colleagues argued that carcinogen-induced changes 
must happen in single crypts, which will show altered structure (as width, height, 
thickness, and luminal opening) due to genomic instability and aberrant cell 
growth. It was hypothesized that the more such aberrant crypt areas or foci 
(ACFs) grow dysplastic, the larger the chances of colon tumor development 
becomes [47-49].  
Furthermore, cells from dysplastic ACFs were found to over-express 
cytoplasmic/nuclear β-catenin and nuclear cyclin D1 [43-44,50], as well to have 
a significant apoptosis increase [51]. In humans, dysplastic ACFs were revealed 
to be hyperproliferative lesions with high gene and protein expression for the 
proliferating cell nuclear antigen (PCNA), epidermal growth factor receptor 
(EGFR), transforming growth factor-alpha (TGF-α), and cyclin D1 [52]. Thus, 
dysplastic ACFs are hyperproliferative preneoplastic lesions with high cell 
turnover, moving the cryptal proliferation zone from the bottom to the epithelial 
surface [52-56].  
Altogether, ACFs develop into dysplastic form and precede the 
development of adenomas which give rise to adenocarcinomas or colon tumors 
[43-44,46,50,57].  
1.4.2  Colon preneoplastic lesions and stromal areas 
Colon preneoplastic lesions are surrounded by stromal areas besides 
normal crypts [47]. In general, stromal areas are composed of a large number of 
fibroblasts and endothelial cells providing epithelia with physiological or 
pathological signals. During carcinogenesis, stromal cells were suggested to 
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induce a transition of non-malignant cells towards a malignant state [58-59]. 
This is normally related to the acquisition of a stromal reactive phenotype, in 
which stromal cells reorganize the stroma architecture by upregulating the 
release of growth factors, which enhances the preneoplastic neovascularization 
process [58,60]. This concept was demonstrated in skin carcinogenesis, where 
hyperplastic, dysplastic, and invasive lesions were accompanied by the 
reorganization of stroma architecture and an angiogenic hyperactivation [60].  
In colon tumorigenesis stromal areas were observed to acquire a 
reactive phenotype which enhanced the epithelial transformation from normal to 
in situ invasive carcinoma [61-62]. Experiments with orthotopic transplantion of 
mesenchymal stem cells (MSCs) have shown that MSCs cells migrate into 
stromal areas and differentiate into carcinoma-related fibroblasts, which mainly 
tumor growth by enhancing angiogenesis [63]. It was also found that a therapy 
which targeted the platelet-derived growth factor (PDGF)-receptor β therapy 
reduced tumor growth by controlling stromal reactivity, for example by 
decreasing the microvessel density   [64]. Thus, this framework involving stroma 
and tumor components stimulates cancer cells to re-activate cancer stem cell 
(CSC) features and simultaneously induce the invasion and spread of the 
malignancy into the surrounding tissue [65-66]. 
1.4.3  Tumor metabolism   
Hyperproliferative growth rates seem to be the main event allowing 
tumors to grow [52-56,67-68]. However, tumors need high and quick ATP 
generation to proliferate, besides a tightened maintenance of cell redox status, 
and enhanced biosynthesis of macromolecules. Basically, tumors shift their 
energy generation machinery from oxidative phosphorylation to an aerobic-
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glycolytic metabolism [69-70]. This strategy allows tumors to keep a high ATP 
generation avoiding the negative feedback regulation from overusing glycolysis 
[69].  
Specifically, tumors enhance the enzymatic activity of glucose 6-
phosphate dehydrogenase (G6PDH) that transforms glucose to glucose-6-
phosphate (G6Pase) and then to 6-phosphogluconolactone. This reaction is 
specifically intermediated by the transition of NADP+ to NADPH. This means 
that transiting NADP+ to NADPH further transforms 6-phosphogluconolactone 
to ribose-5-phosphate (R5P), which in turn increases nucleotide synthesis and 
DNA repair. Besides, G6Pase can be transformed to fructose-6-phosphosphate 
and glyceraldehyde-3-phosphate, which also enhances glycolysis and NADPH 
generation [69-70] 
Overall, tumor cells thus undergo deep metabolic changes on way to 
survive in the stressful tumoral microenvironment [70].  
1.4.4  Hypoxia, metabolism, and intracellular pH   
Hypoxia is a term used to characterize situations of low oxygen levels in 
tissue, tumors, or cell cultures [71-74].  In tumors, high proliferation enlarges the 
distance between cells and microvessels reducing the oxygen and nutrient 
supplies, starting a hypoxic microenvironment. While this promotes the 
expression of growth factors inducing neovascularization, hypoxic areas are 
nonetheless present and are enhanced due to the chaotic and malformed 
structures of tumoral vessels and microvessels [74]. This situation of low 
oxygen tissue levels stimulates oxygen-dependent and independent 
mechanisms that alter several molecular signaling pathways [42,56,75].   
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Moreover, hypoxic tumor cells are known to use glycolysis in order to 
increase energy generation. This requires an over-activation of glucose 
transporters (i.e., GLUT1), lactate transporters (i.e., MCT4) and lactate 
dehydrogenase A (LDH-A) through the hypoxia-inducible factor 1 (HIF-1) 
transcriptional activity. By inhibiting the degradation of HIF-1, which upregulates 
the glycolysis-related molecular activities, tumor cells increase the conversion of 
pyruvate to lactate, thereby enhancing glycolysis [71,74]. However, tumor cells 
then would suffer from the hypoxia-induced and glycolysis-related acidosis. 
Therefore, they alkalinize their ipH on way to survive and proliferate. This is 
achieved via hyperactivation of HIF-1 activity, which enhances the hydration of 
carbon dioxide (CO2) to bicarbonate by the catalytic activity of carbonic 
anhydrase (CA) IX and XII enzymes and promotes the activity of MCT-4 to 
extrude lactate and H+ ions, both supporting an intracellular pH (ipH) 
alkalinization [74,76]. 
 
 
 
 
 
 
 
 
 
 
21 
 
2 Aims 
 
Considering that very little is known about how FLX acts against colon 
tumor development, we propose herein: 
To verify whether FLX has antioxidant, pro-oxidant or DNA-damaging 
potential in standard toxicological assays; 
To check whether and how FLX can prevent and reduce colon 
preneoplastic lesions; this means that besides dysplasia and epithelial 
proliferation, preneoplastic angiogenesis will be our target of study; 
To ascertain whether FLX has any oncostatic potential against colon 
tumors; here, we will focus on how the modulation of tumor energy generation-
related events could affect tumoral proliferative processes;  
To investigate whether FLX activity is comparable with a known and 
currently applied chemotherapeutic agent against colon cancer.   
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3 Material and Methods 
3.1 Fluoxetine stock solution preparation 
FLX was acquired from Sigma-Aldrich (Germany). For a cell culture 
treatment, for example an amount of 10 mg FLX was dissolved in 646,5 µL 
dimethylsulfoxide (DMSO; Sigma-Aldrich, Germany). It provided a stock 
solution of 50 mM. Aliquots of 20 µL were prepared and kept at -20°C. For in 
vivo experiments, FLX solutions were prepared daily. Thus, the mean weight 
(MW) of each group was calculated and the FLX amount adjusted to 30mg/Kg 
(30xMW/1000). Around 200 µL were calculated for treating each animal 
(gavage or injection). From the final volume, 10% were used for solvent [100% 
ethanol (rats) or DMSO (mice)] and another 90% for vehicle (standard saline 
solution, 0,9% sodium chloride).       
3.2 Ferric reducing antioxidant power assay 
The reducing reaction of a ferric-tripyridyltriazine complex to its ferrous 
form was used to test the antioxidant potential of FLX, according to the standard 
method of our laboratory [77]. Briefly, FLX stock solutions were adjusted in 20 
μL to final concentrations of 1, 10, or 100 µM, and mixed afterwards to 180 µL 
of water. Next, 600 μL of freshly prepared ferric reducing antioxidant power 
(FRAP) solution [25 mL of 300 mM acetate buffer, pH 3.6, 2.5 mL of 20 mM 
ferric chloride hexahydrate dissolved in distilled water, and 2.5 mL of 10 mM 
2,4,6-tripyridyl-s-triazine (TPTZ) dissolved in 40 mM hydrochloric acid (HCl)] 
were added to the first 200 µL mixture. Then, the solution was incubated at 
room temperature for 5 or 30 min. Absorbance was measured at 595 nm with a 
spectrophotometer (Bio-Tek, Model Uvikon XL, Germany). Results are given as 
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FRAP in μmol/L. Tempol (50 μM) was used as positive control, and distilled 
water as blank. 
3.3 Cell culture 
Cell cultures were kept under standard conditions (normoxia; 5% CO2; 
95% air; 90% humidity), or hypoxia (1% oxygen (O2); 5% CO2; 94% NO2; 
incubator C42, Labotect GmbH, Göttingen, Germany) at 37 °C. The use of both 
conditions was according to the experimental designs (I, II, and III). 
Subculturing cell lines was performed twice a week, and mycoplasma 
contamination was checked monthly. Cells were seeded into 6-well plates 
(Sarstedt Inc., Newton, USA) or 25-cm2 flasks at a suitable initial concentration 
for each of the three different cell lines, and were left untreated for 20 to 24h 
before performing experiments.   
3.3.1 Cell lines  
3.3.1.1 V79 hamster fibroblast cell line 
V79 cells were provided by Dr. Alexander Eckhardt/Prof. Helmut 
Schweikl (University of Regensburg, Germany). After thawing, cultures were 
initiated by seeding 5x105 cells in 25-cm2 cell-culture flasks with 5 ml minimal 
essential media (MEM) with 10% fetal calf serum (FCS; Biochrom AG, 
Germany), glutamine, and antibiotics. Cell cultures were kept under normoxia at 
37 °C. Cells were seeded at an initial concentration of 3x105 cells before 
experiments. 
3.3.1.2 HT29 human colorectal adenocarcinoma cell line 
The HT29 cells were obtained from the American Type Culture 
Collection (ATCC; USA) and cultured under standard conditions and grown in 
Dulbecco's modified eagle media (DMEM; 4.5 g/L glucose). The culture medium 
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was supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 
antibiotics. Cells were seeded at an initial concentration of 5x105 cells before 
experiments.   
3.3.1.3 Caco-2 human colorectal adenocarcinoma cell line 
Caco-2 cells were obtained from ATCC and grown under standard 
conditions in Eagle’s MEM medium  supplemented with 20% FBS, 1% L-
glutamine, 1% Na-pyruvate, 1% nonessential amino acids, and antibiotics. Cells 
were seeded at an initial concentration of 3x103 cells before experiments.  
3.3.1.3.1 Experimental design I 
V79 and HT29 cells were seeded into 6-well plates under normoxic 
conditions, and left untreated up to 24h before experiments. Then, cells were 
treated with 1, 10 or 100 µM FLX. According to experimental aims, positive 
controls were resveratrol (Res; 60 µM), hydrogen peroxide (H2O2; 100 or 200 
µM), sodium arsenite (NaASO2; 100 µM), or Antimycin A (AntiM; 10 µM). 
Experiments were performed for 30min, 4h or 24h.  
3.3.1.3.2 Experimental design II 
HT29 and Caco-2 cells were seeded into 6-well plates under normoxic 
conditions, and left untreated up to 24h before experiments. Then, cells were 
exposed to 10 or 20 µM FLX, and/or 10 µM AntiM for 30min.  
3.3.1.3.3 Experimental design III 
HT29 and Caco-2 cells were seeded into 6-well plates, and underwent 
normoxia or hypoxia exposure up to 24h before experiments. The same 
conditions were used to expose cells to 20 µM FLX for 30min or 24h. Hypoxia 
was used as positive control for oxidative effects.  
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3.3.2  Analytical methods 
3.3.2.1 Flow cytometry 
For each experiment, 20,000 cells were analyzed per sample with a 
Becton Dickinson LSR ITM (BD; Heidelberg, Germany) flow cytometer together 
with BD CellQuest ProTM software. At least four independent experiments were 
carried out for each endpoint. 
3.3.2.1.1 Detection of reactive oxygen species generation  
Detection of ROS generation was performed by staining cells for 10 
minutes with 10 µm 2′, 7′-Dichlorodihydrofluorescein diacetate (H2DCF-DA) in 
culture medium in 3ml medium/well. After harvesting, cells were washed twice 
(1000 rpm, 4°C, 5 min) with phosphate buffered saline (PBS) + 1% bovine 
serum albumin (BSA), and, then analyzed by flow cytometry. An argon laser 
excited cells at 488 nm (300 – 400 mW power), and emission was detected with 
a 530 nm (FL1) band pass filter. 
3.3.2.1.2 Annexin V/Propidium iodide assay 
A viability and apoptosis assay was performed by an Annexin V/PI kit, 
according to the manufacturer's instructions. 
3.3.2.1.3 Detection of superoxide  
Detection of superoxide (O2
-) was performed by staining cells for 30 
minutes with 10 µM dihydroethidium (DHE) in 3ml PBS or medium without 
serum/well. A flow cytometer equipped with an argon laser was used for 
analysis, and emission was detected with a 575 nm (FL2) band pass filter [78].  
3.3.2.1.4 Intracellular pH analysis  
Manufacturer’s instructions were followed to stain cells with 10 µM 
2′,7′‑bis‑(2‑carboxyethyl)‑5‑(and‑6)‑carboxyfluorescein acetoxymethyl ester 
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(BCECF-AM, B-1150; Molecular Probes, Invitrogen, Germany) for 20 min at 37° 
C under constant shaking. Before this, cells were treated with 1%DMSO or FLX 
for 30 min in complete medium. After harvesting, cells were washed twice (1000 
rpm, 4°C, 5 min) with Earl’s balanced salt solution (EBSS), then stained with 
BCECF-AM. Calibration curve was achieved by washing untreated cells with 
high-[K+] buffers at pH values of 6.6, 7.0, and 7.6. Cells were kept in these 
buffers during staining procedure. Afterwards, cells were washed and analyzed 
by flow cytometry with an argon laser (200 mW power), and band pass filters of 
530 nm (FL1) and 670 nm (FL3). The FL1/FL3 ratio was considered to reflect 
ipH alterations. 
3.3.2.1.5 Mitochondrial membrane potential analysis 
The alteration of the mitochondrial membrane potential (ΔΨm) was 
detected with the dye JC-1 according to the manufacturer's instructions. Briefly, 
cells were gently washed and kept in PBS with 3 µM JC-1, and 1% DMSO or 20 
µM FLX for 30 min. Then, cells were washed twice and analyzed by flow 
cytometry as described above. The FL1/FL3 ration was used as ΔΨm.  
3.3.2.1.6 Cell-cycle analysis  
FLX-treated and control cells were harvested, permeabilized 
(Cytofix/Cytoperm kit), and stained with 2.5 µM bisbenzimide for 30 min. A 
HeCd UV laser excited cells at 325 nm, whilst emission was detected with a 424 
nm (FL5) band pass filter. Cell cycle phases were determined with the ModFit 
LTTM software package (Verity Software House, USA). 
3.3.2.2 Viability test  
A morphological assessment of cell viability was performed. In brief, 
cells were incubated for 24 h with the desired compounds in 3 ml of complete 
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medium. After harvesting, cells were applied onto glass slides by cytospin 
centrifugation, and fixed in cold methanol (-20°C; 2 h). Before counting, cells 
were stained for 3 minutes with Gel Green (62.5 μl/ml in Sørensen buffer, pH 
6.8), washed twice with Sørensen buffer (15 mM disodium phosphate 
(Na2HPO4) and 15 mM monopotassium phosphate (KH2PO4), pH 6.8) and 
mounted for microscopy. From each of two slides, the morphology of 1000 cells 
was evaluated for occurance of mitosis, apoptosis, or necrosis. Numbers were 
expressed as percentages of all analyzed cells.  
3.3.2.3 Comet Assay 
A standard alkaline version of the comet assay was performed. Hence, 
20 μl harvested cells were mixed with 180 μl low melting agarose (0.5 %). This 
mixture was added to SuperFrost slides (covered with a layer of normal melting 
point agarose [1%]). Slides were incubated at 4°C for 1h in 60 ml lysis buffer 
[2.5 M sodium chloride (NaCl), 0.1 M ethylenediaminetetraacetic acid (EDTA), 
0.01 M tris(hydroxymethyl)aminomethane (Tris) and 1 % Triton X-100, 10 g/l N-
lauroylsarcosine sodium adjusted to pH 10 with sodium hydroxide (NaOH)]. 
Then, slides were washed, and placed within a special electrophoresis reservoir 
for 20 min in electrophoresis buffer (300 mM NaOH, 1 mM EDTA, pH > 13.0). 
Afterwards, electrophoresis was performed for 20 min at 25 V (1.1 V/cm) and 
300 mA. Slides were neutralized in 0.4 M Tris buffer (pH 7.5), dehydrated in 
methanol at -20°C for 10 min, and left to dry at 37°C for 1h. Slides were stained 
with 20 μl of Gel-Red/Dabco-solution (1:3; Biotrend, Germany). During 
evaluation, 100 cells were selected randomly (50 cells per replicate) for each 
sample, and analyzed at 200-fold magnification with fluorescent microscopy 
(Labophot 2, Nikon, Germany) connected to Komet 5 software (BFI Optilas, 
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Germany). The percentage of DNA in the tail was used to quantify DNA 
migration. 
3.3.2.4 Western blotting analysis  
Cell cultures were washed and then directly lyse in 1X 
radioimmunoprecipitation assay (RIPA) buffer (150mM NaCl, 3mL; 20mM Tris, 
pH7.5, 2mL; 1mM EDTA, 200µL; 1%NP-40, 1mL; 1%DOC, 1g; 0.1%SDS, 1mL; 
5mM NaF, 12.5mg; 100mL distilled H2O ). WB analysis was performed as 
described in NuPAGE Technical Guide (Invitrogen, USA). Briefly, protein 
extracts were run on NuPAGE 4-12% Bis-Tris Mini Gels (Invitrogen), and 
transferred to membranes with iBlot Dry Blotting System (Invitrogen).The 
membranes were incubated 4°C overnight with anti-p27 (D69C12, Cell 
Signaling, USA), anti-Cyclin E (HE12, Cell Signaling), and anti-GAPDH (9484, 
Abcam, UK) or anti-β-Actin (13E5, Cell Signaling) antibodies. Secondary 
antibodies (goat anti-rabbit and goat anti-mouse IgG HRP antibodies) were 
incubated for 1h at room temperature. Bands of labeled antibodies were 
detected by using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific, USA). Films were scanned and intensity of bands quantified 
with ImageJ software (National Institutes of Health, NIH, USA). 
3.4 Animal experiments 
All experimental protocols were approved by the Animal Care and Use 
Committee from the Medical School, University of São Paulo. Approvals were 
numbered subsequently as n° 150/2008 for Wistar rats, n° 068/2012 for 
C57BL/6 mice, and n° 121/2012 for nonobese diabetic severe combined 
immunodeficient (NOD/SCID) mice. All animals were acclimated for 1 week 
before starting the experiment, housed from 4 to 6 per plastic cages with 
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softwood chips used as bedding at 22+ 2oC (55% huminity and 12 h light/dark 
cycle), allocated randomly into their respective groups, and had free access to 
chow and water. 
3.4.1  Wistar rats 
Male Wistar rats (150-160 g) were assigned to control (CTRL), DMH 
treatment (a single dose of dimethylhydrazine [DMH;125 mg/kg; i.p.] in the 
second week from the beginning of the experiment), FLX treatment (given a 
daily FLX gavage [30mg/kg] for 6-weeks.) or DMH+FLX treatment groups. All 
rats were euthanized by CO2 exposure after 6 weeks from the first FLX gavage. 
Individual autopsies were performed, and colon tissue samples were fixed in 
formaldehyde-buffer (4%; 24 h). Rats with fragmented tissue sections were 
discarded from the analysis.  
3.4.2 C57BL/6 mice 
Groups of female C57BL/6 mice (25 g) consisted of control (CTRL) 
animals or received methylnitronitrosoguanidine (MNNG) treatment (four 
successive doses of MNNG [5mg/ml; intrarectal deposits of 100 l] twice a 
week for 2 weeks), FLX treatment (30mg/kg/day; intraperitoneal, i.p.) or 
MNNG+FLX treatment. FLX treatment was started after 2 weeks from the end 
of MNNG treatment, and continued for the next 4-weeks. All mice were 
euthanized by CO2 exposure at week 8. Individual autopsies were performed, 
and colon tissue samples were fixed in paraformaldehyde buffer (4%; 24 h).  
3.4.2.1 Analytical methods 
The following methods were used for analyzing samples from Wistar 
rats and C57BL/6 mice.  
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3.4.2.1.1 Histopathological analysis  
Colon tissue samples were sectioned from paraffin blocks and stained 
with hematoxylin and eosin (H&E) according to standard procedures for 
analysis under light microscopy. A first analysis was carried out at 200x 
magnification in transversal colonic sections, giving an en face overview of the 
tissue.  Dysplastic ACFs were detected and enumerated according to 
pathological features, as ranging from mild to severe dysplasia [43]. Afterwards, 
a second analysis was carried out at 400x magnification for each detected ACF 
for confirmation of dysplastic features and counting the number of aberrant 
crypts (AC). Microvessels (MV) were counted at 400x magnification in 
horizontal sections from rats, and transversal sections from mice. The whole 
area of each analyzed section was determined with a graduated lens (100x; 
Carl Zeiss, Germany; Nikon, Japan), and its area (m2 or mm2) was calculated 
as values (V) x 5 for analysis with Carl Zeiss graduated lens (rats), or values (V) 
x 0.9801/121 for analysis with Nikon graduated lens (mice). 
In rats, relative values for dysplasia are shown as total number of 
lesions per m2. Microvessels were enumerated in horizontal sections. In mice, 
relative values for ACF-i (index), AC-i, and MV-i were calculated as their total 
number per mm2 [79-80]. The vascularization-related dysplasia was determined 
to be ACF x MV/ AC. 
3.4.2.1.2 Immunohistochemistry and immunofluorescence  
A standard method for immunohistochemistry (IHC) was performed in 
tissue samples. In brief, paraffin-embedded tissue sections (4m) were 
mounted on SuperFrost slides, and dried at 56°C for 30 min. Sections were 
deparaffinized in xylene bath (100%), then rehydrated in graded ethanol (100 to 
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80%) and water baths. Tissue endogenous peroxidases were blocked 
incubating sections in 3% H2O2 for 20 min. Antigen retrieval was achieved 
incubating sections in a citrate buffer (pH 6.0) at 98°C for 40min, and cooling at 
room temperature for 30 min. Prediluted horse serum (1:50) was used for 
blockage against nonspecific endogenous protein binding.  
The primary antibodies against Ki67 (clone MMA), PCNA (clone PC 
10), c-Myc (clone 9E11), CD34 (clone QBEnd), and CD31 (clone 1A10) were 
purchased from Novocastra (USA). Anti- nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB,p50; clone C-19), nuclear factor of kappa 
light polypeptide gene enhancer in B-cells inhibitor, alpha (IB-clone N-20), 
IB-(clone H-4), and vascular endothelial growth factor (VEGF; clone A-20) 
antibodies were acquired from Santa Cruz Biotechnology (Heidelberg, 
Germany). Anti-CD133 antibody was from Biocare Medical (USA). Picture-MAX 
Polymer Kit was purchased from Invitrogen (USA). These primary antibodies 
were used for IHC staining. 
To perform the immunofluorescence (IHF) staining, mouse anti-human 
CD133 primary antibody was acquired from Miltenyi Biotec (n°130-090-422; 
Germany), and secondary anti-mouse FITC conjugated antibody from Dianova 
(n° 715-095-150; Germany); rabbit anti-mouse VEGF antibody was purchased 
from Santa Cruz (clone sc-152; Germany), and secondary anti-rabit Cy3 
conjugated antibody from Dianova (n° 111-165-144); rat anti-mouse CD34 and 
rabbit anti-mouse CD31 antibodies were acquired from Applied Biosystems (n° 
ab 8158 and ab 28365; Germany); secondary anti-rat Texas Red conjugated 
antibody was purchased from GeneTex (n° GTX 26732; Germany), and 
secondary anti-rabitt Cy3 conjugated antibody from Dianova (n° 111-165-144).  
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During IHC staining, sections were incubated (1:100) with anti-Ki67, 
anti-PCNA, anti-c-Myc, anti-NF-kB, anti-IB-, anti-IB-, anti-CD133, anti-
VEGF, anti-CD34, and anti-CD31 primary antibodies overnight. The brown color 
was displayed by incubating sections with Picture-MAX Polymer Kit for 1h, and 
DAB for 30sec. Sections were counterstained with hematoxylin. For negative 
controls, the primary antibody was omitted, and positive tissue controls were 
used in according to manufacturer's instructions of each antibody.  
In positive reactions a brown precipitate at the nucleus was detectable 
(x200 magnification) for Ki67, PCNA, and NF-B (analyzed at x1000 
magnification), and in the cytoplasm and/or perinuclei for c-Myc, IB-, IB-, 
CD133, VEGF, CD34, and CD31. Analysis performed in epithelia was 
expressed as a ratio between positively stained nuclei to total unstained nuclei, 
whereas analysis in stromal colon areas was performed as a ratio between total 
positive cells and number of counted areas. Nuclear-transitional activity for NF-
B protein, within stromal areas, was calculated as a ratio between positively 
stained nuclei to cytoplasmic positive cells.  
Double-labeling (IHF) was performed in fixed colon samples labeled 
with mouse anti-human CD133 (1:100; secondary anti-mouse FITC conjugated 
antibody; 1:400), rabbit anti-mouse VEGF (1:100; secondary anti-rabitt Cy3 
conjugated antibody; 1:400), rat anti-mouse CD34 (1:100; secondary anti-rat 
Texas Red conjugated antibody; 1:400), and rabbit anti-mouse CD31 (1:100; 
secondary anti-rabitt Cy3 conjugated antibody; 1:400, Dianova) antibodies. 
Nuclei were stained with DAPI. Images were acquired with an Olympus BX51 
microscopy equipped with anOlympus DP71 camera and a CellSens Dimension 
software (Olympus, Germany). 
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Rats or mice with fragmented tissue sections were discarded from the 
analysis 
3.4.2.2 Nonobese diabetic severe combined immunodeficient 
mice 
NOD/SCID mice (20g) were maintained under specific pathogen-free 
conditions. For colon xenograft-tumors, 1.5x106 HT29 or Caco-2 cells (50-60% 
confluence; 200L) were injected subcutaneously into shaved areas at the back 
of the mice. Tumor growth was monitored daily a caliper. Pharmacological 
treatment was initiated when the tumors achieved a mean volume of around 
21.4 cm3 for Caco-2 xenograft-tumors, and 0.13 cm3 for HT29 xenograft-tumors.  
3.4.2.2.1 First experiment – Caco-2 xenograft-tumors 
During the first experiment, mice bearing Caco-2 xenograft-tumors were 
divided into a ontrol group [CTRL; receiving a daily intraperitoneal (i.p.; 200 µL) 
injection of saline solution], and an FLX treatment group [daily dose of 
30mg/kg/day (i.p.) for 6 days]. On the seventh day, the mice were sacrificed in a 
CO2 chamber. Serum was collected by centrifuging blood samples (835g, 
10min, 4°C). Tumor tissue samples were fixed in formalin or frozen in liquid 
nitrogen. All frozen samples were kept at -80°C. 
3.4.2.2.2 Second experiment – HT29 xenograft-tumors 
The second experiment was performed with mice bearing HT29 
xenograft-tumors. Mice were divided into control group (CTRL), and an FLX 
treatment group. The treatment group received the same daily FLX dose as 
described above for 3 days. On the fourth day mice were sacrificed as 
described above.  
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3.4.2.2.3 Third experiment – HT29 xenograft-tumors 
A third experiment was performed with mice bearing HT29 xenograft-
tumors to compare FLX induced effects with those of a known 
chemotherapeutic agent (5-Fluorouracil, 5-FU; 50 mg/kg/day). FLX treatment 
was applied as described above. During sacrifice, the mice underwent general 
anesthesia [1,5% isoflurane (Forane® Abbott GmbH & Co, Germany) in 98,5% 
oxygen; 2l/min] before receiving a cardiac puncture for blood collection. Serum 
was prepared as described in section 3.4.2.2.1. Tissue samples for protein 
extraction were directly frozen in liquid nitrogen. For RNA extraction, tissue 
samples were frozen in RNAlater RNA stabilization buffer (Qiagen, Germany) 
with liquid nitrogen, or within Tissue-TEK (Sakura Finetek, Netherlands) for 
histological preparations. 
3.4.2.2.3.1 Monitoring of xenograft-tumors   
Tumor volume was monitored by measuring the tumors with a caliper on 
the first (initial volume, IV) and seventh days (final volume, FV) for NOD/SCID 
mice bearing Caco-2 xenograft-tumors, or on the first and fourth days for those 
bearing HT29 xenograft-tumors. Values were calculated according to the 
formula volume = π x L x W x T/6 (where L is length; W is width; and, T is 
thickness). The relative tumor growth (RTG) was calculated according to the 
formula, RTG = FV-IV/number of days.  
3.4.2.2.4 Analytical methods 
3.4.2.2.4.1 Histopathological analysis  
After standard H&E staining, three different areas were classified in 
each colon xenograft-tumor section: Invasive Front (IF), which was determined 
as a cell population at the border of the tumors; Tumor Parenchyma (TP), which 
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was determined as areas composing the inner part of the tumors, as associated 
with a high-density cell population; Peri-Necrotic (PN) area, which was detected 
as non-dense areas surrounding the irregular and widespread necrotic foci. PN 
cells were in close and direct contact with necrotic areas, and clustered in cell 
sets, which were generally separated between themselves and from TP areas 
by thin non-proliferative cell layers. Fig. 20 and 31 illustrate this classification in 
the results section. 
3.4.2.2.4.2 Immunohistochemistry and immunofluorescence  
Immunehistochemical and -fluorescence detections were performed as 
described above (section 3.4.2.1.1.2). Positive Ki67 nuclei were manually 
counted throughout pictures (3.15 mm2) taken at 400x magnification from five 
randomly chosen microscopic fields. A ratio between stained nuclei and 
pictured areas was established as tumor proliferation rate. Tumor necrotic areas 
were excluded from counting.   
3.4.2.2.4.3 Western blotting analysis of xenograft-tumor samples 
Caco-2 xenograft-tumors (section 3.4.2.2.1) were macerated in liquid 
nitrogen and lysed directly in 1mL of lysis buffer (1X RIPA) with 1% protease 
inhibitor cocktail solution (Sigma-Aldrich, USA). The lysates were centrifuged at 
14,000 x g for 20min and the supernatant was stored at −80°C. The soluble 
proteins were then measured following the manufacturer’s protocol of 
bicinchoninic acid (BCA Protein Assay Reagent (Thermo scientific Rockford, IL, 
USA). Total cellular protein (50 μg) was separated by electrophoresis through a 
10% SDS–PAGE resolving gel. For Western blot analysis, the proteins were 
transferred onto a polyvinylidene fluoride (PVDF) membrane (Gelman Science), 
and the blotting was performed with a snap identification protein detection 
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system (Millipore, USA), following the manufacturer’s protocol. Briefly, the 
membranes were blocked for 20min and then incubated for 10 min with anti-NF-
KB p-50 (goat polyclonal antibody 1:400, Santa Cruz Biotechnology, USA), 
washed  and then incubated with secondary antibody (anti-rabbit IGg and anti-
goat IGg respectively), conjugated to horseradish peroxidase (1:2000, Santa 
Cruz Biotechnology, USA). -tubulin (rabbit polyclonal antibody 1:3000, Santa 
Cruz Biotechnology, USA) was used as a loading control. The optical densities 
of the protein bands were detected using enhanced chemiluminescence ECL 
(PerkinElmer, USA) and were obtained and measured using the ImageQuant 
350 device and software from GE Healthcare (General Electric, USA).  
Frozen-tumor tissue samples (section 3.4.2.2.3) were sectioned and put 
into 2mL eppendorf tubes with lysis buffer (1x RIPA) and a 5 mm stainless steel 
bead (Qiagen, Germany). Eppendorfs tubes were inserted in a TissueLyser 
Qiagen system according to the manufacturer's instructions (Qiagen, Germany). 
The following procedures were performed as described above (section 3.3.2.4). 
Membranes were incubated with anti-p27, anti-Cyclin E, and anti-β-Actin 
antibodies.  
3.4.2.2.4.4 MILLIPLEX assay for human oxidative phosphorylation 
and protein kinase B/mammalian target of rapamycin phosphoprotein 
signaling  
Tumor protein extraction was performed as described above (section 
3.4.2.2.4.3). MILLIPLEX® human oxidative phosphorylation (OXPHOS; Cat. N° 
H0XPSMAG-16K) and protein kinase B (Akt)/mammalian target of rapamycin 
(mTOR) phosphoprotein magnetic bead panel kits (Cat. N° 48-611MAG) were 
bought from Merck Millipore (Germany). The applied protein concentrations 
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were 60 μg/mL for OXPHOS assays, and 300 μg/mL for Akt/mTOR analyses. 
Sample preparations and data collection were performed according to the 
manufactures’ instructions.  Values are given as median fluorescence intensity 
(MFI) collected from replicates during analysis of the tumors samples.  
3.4.2.2.4.5 Quantitative real-time reverse transcription-polymerase 
chain reaction  
Frozen tissue samples were thawed and taken out of the RNAlater RNA 
stabilization buffer (Qiagen, Germany). Samples were put into 2mL eppendorf 
tubes with lysis buffer (RTL; Qiagen, Germany) and a 5 mm stainless steel 
bead (Qiagen, Germany). Eppendorfs tubes were inserted in a TissueLyser 
Qiagen system according to the manufacturer's instructions (Qiagen, Germany). 
The supernatant was collected and added to sterile 1.5mL eppendorf tubes. 
Pure RNA was prepared with a fully automated sample preparation QiaCube 
system (Qiagen, Germany). Pure RNA was used to synthesize cDNA applying 
an iScriptTM cDNA Synthesis Kit (BIORAD, Germany). Primers for translocase of 
outer mitochondrial membrane 20 homolog (TOMM20; QT00088914), GLUT1 
(QT00068957), MCT4 (QT00044044), LDHA (QT00001687), NADPH oxidase 1 
(NOX-1; QT00025585), and HIF-1 (QT00083664) were bought from QIAGEN 
(Germany), and amplified using a with QIAGEN kit for SYBR Green-based qRT-
PCR technology according to the manufacturer's instructions (QIAGEN, 
Germany). Total RNA input was normalized based on Ct values for 18s 
housekeeping gene, as a reference standard. The 18s primer control was 
bought from Biomers (Germany; Forward sequence: tca aga acg aaa gtc gga 
ggt tcg; Reverse sequence: tta ttg ctc aat ctc ggg tgg ctg). All quantitative real-
time reverse transcription-polymerase chain reaction (qRT-PCR) reactions were 
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duplicated, according to the standard procedure. Data were collected and 
analyzed using a DNA Engine Opticon 2 Real-Time Cycler PCR detection 
system (MJ Research, USA) together with Opticon Monitor 2 software package. 
The fold change was calculated using the 2-∆Ct method. 
3.4.2.2.4.6 Biochemical measurements  
Serum and tumor samples were prepared as described in the sections 
3.4.2.2.1 and 3.4.2.2.4.3, respectively. Then, glucose (mg/dL) and lactate 
(mmol/L) were determined by standard methods [glucose and lactate monitoring 
system (Precision Xtra, Abbott Laboratories, Abbott Park, U.S.A.) together with 
corresponding test strips (Abbott GmbH & Co. KG, Germany)] in a certified 
clinical chemistry laboratory (Zentrallabor des Universitätsklinikums Würzburg; 
Gerinnungsambulanz Zentrum Innere Medizin, A4, Oberdürrbacher Strasse 6, 
Würzburg). To estimate the glycolytic metabolism a ration between glucose and 
lactate was calculated for each sample.  
3.4.2.2.4.7 Statistical analysis  
Data were analyzed using the statistical GraphPad Prism 5.0 software 
package (Graph Pad Software Inc., San Diego, California, USA). Comparison of 
data from two different groups was performed with a Mann Whitney test. 
Results from multiple different groups were analyzed with a One-way ANOVA, 
and post hoc tests were chosen according to sample distributions. Analyzing 
different categorical independent variables on one dependent variable was 
performed with a Two-way ANOVA test and Bonferroni post hoc test. A 
probability of P<0.05 was considered to be statistically significant. All values 
represent means + standard deviations. 
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4 Results 
4.1 FLX does not show antioxidant, pro-oxidant or DNA-
damaging potential  
We first investigated whether FLX has antioxidant properties with a cell-
free FRAP-assay. After 5min exposure, all FLX concentrations yielded lower 
Fe3+ reduction values than the control (Figure 1A). After 30min exposure, 
values were similar to the control (Figure 1B). Tempol was used as positive 
control, and the difference to that was significant for all tested FLX 
concentrations.   
 
Figure 1 – Cell-free FRAP-assay after 5 min [A; *P > 0.05 vs 0 µM (blank); # # #P 
> 0.001 vs 50 µM Tempol], and 30 min [B; # #P > 0.01 and # # #P > 0.001 vs 50 
µM Tempol] treatment with FLX or Tempol (positive control). 
 
Next, we evaluated whether FLX can modulate GSH levels in V79 cells. 
Flow cytometry analysis showed that 1 or 10 µM FLX treatment for 4h or 24h 
did not alter GSH intracellular levels (Figure 2A), while 100µM FLX treatment 
reduced GSH levels significantly in comparison with H2O2-exposed cells after 
24h (Figure 2B). Resveratrol (Res) was applied as positive control. Cell viability 
was also checked for FLX treatment in V79 cells after 24h. None of the applied 
FLX-concentrations induced significant differences in the numbers of mitosis or 
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apoptosis; while 10 µM FLX treatment decreased necrosis 3-fold compared with 
DMSO-exposed cells (Figure 2C).   
 
Figure 2 – GSH levels were analyzed by flow cytometry after 30min treatment 
(A) or 4h treatment (B) with FLX or Resveratrol (Res, positive control) (A; *P < 
0.05, **P < 0.01, and ***P < 0.001 vs 50 µM Res; # #P < 0.01 vs 200 µM H2O2). 
Cell viability was analyzed by microscopy after exposure to FLX (or NaASO2 as 
positive control) for 24h (C; P > 0.05). DMSO = solvent control (< 1% final 
concentration of DMSO). 
 
Then, we investigated the potential of FLX to induce ROS generation. 
Up to 100µM FLX did not induce ROS after 30min or 4h (Figure 3A and 3B).  
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Figure 3 – Oxidative stress assay with V79 cells applying flow cytometry and 
the dye H2DCF-DA. Experiments were performed for 30min (A; *P > 0.05 and 
**P > 0.01 vs 200 µM H2O2), and 4h (B; *P > 0.05 vs 200 µM H2O2) with H2O2 
as positive control. DMSO = solvent control (< 1% final concentration of 
DMSO). 
 
By using the comet assay for investigation of DNA-damaging potential it 
was observed that none of the applied FLX concentrations were able to induce 
significant DNA-damage after 30min or 4h (Figure 4A and 4B). 
 
Figure 4 – DNA-damage shown as percentage of DNA in the tail region in the 
comet-assay after exposure to FLX or H2O2 (positive control) for 30min (A; *P > 
0.05 vs 200 µM H2O2), and 4h (B; P < 0.05).  DMSO = solvent control (< 1% 
final concentration of DMSO). 
 
4.2 Effects of fluoxetine treatment in Wistar rats 
4.2.1  Fluoxetine reduces dysplasia, cryptal proliferation, and 
preneoplastic angiogenesis in dimethylhydrazine-exposed colon tissue  
The chemopreventive potential of FLX was investigated in carcinogen 
(DMH) -exposed rats. It was found that treating rats with FLX for 6-wks (2-wks 
before carcinogen-treatment plus 4-wks afterwards) significantly reduced the 
body weight in comparison with control groups (CTRL, 550.2 + 22.08 g, n = 6; 
DMH, 509 + 35.66 g, n = 6; FLX, 375.60 + 101.6 g, n = 5; DMH+FLX, 407.5 + 
29.6 g, n = 6; P < 0.01 between groups without DMH treatment; P < 0.05 
between groups with DMH treatment). Also, FLX treatment reduced the 
development of colon dysplasia (Fig. 5A and 5B) and cryptal proliferation in the 
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DMH-treated group, while it increased proliferation in the colon tissue of non-
carcinogen treated control rats (Fig. 5C and 5D). 
 
 
Figure 5 – Dysplastic lesion (arrow) showing elongated cryptal luminal opening, 
crowded and pseudostratified nuclei, less nuclear polarity, and lower number of 
globet cells (A). Number of dysplastic lesions are shown per m2 in rats treated 
with DMH (B; **P<0.01 vs DMH without FLX, n= 5; DMH+FLX, n= 5). 
Representative image of colon section stained with anti-PCNA antibody. All 
pictures were taken at 400x magnification and scale bars are 20 m (C). 
Proliferation in colon crypts cells (D; **P< 0.01 vs CTRL without FLX, n=6; FLX, 
n= 5; ***P< 0.001 vs DMH without FLX, n=5; DMH + FLX, n= 6).  
 
Angiogenesis was thereafter evaluated in colon tissue. Microvessels 
(Fig. 6A) were reduced in carcinogen plus FLX-treated rats (Fig. 6B). Besides, 
FLX treatment decreased VEGF expression within stromal areas (Fig. 6C) in 
DMH-treated rats (Fig. 6D).  
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Figure 6 – Representative picture of microvessels within PCCS areas. The 
picture inset (enlarged from the boxed region) shows a microvessel (arrow) 
towards crypt. Picture was taken at 400x magnification, scale bars are 20 m, 
and inset was magnified 4x (A). Microvessel-i (index) is shown per m2 (B; *P < 
0.05 vs DMH without FLX, n= 5; DMH+FLX, n= 5). Representative picture 
shows labeled colon section with anti-VEGF antibody. The picture inset 
(enlarged from the boxed region) shows a positive cell at microvessel wall 
(arrow). Picture was taken at 200x magnification, scale bars are 20 m, and 
inset was magnified 4x (C). VEGF-Li according to labelling index of cells for 
anti-VEGF antibody (D; ***P < 0.001 vs DMH without FLX, n= 4; DMH+FLX, n= 
4). 
 
4.3 Effects of fluoxetine treatment in C57BL/6 mice 
4.3.1  Fluoxetine decreases dysplasia and preneoplastic 
angiogenesis in methylnitronitrosoguanidine-exposed colon tissue  
Based on the data from the DMH-treated rats, we evaluated next 
whether FLX treatment could reduce the development of dysplasia in a 
carcinogen model which is not related to hepatic metabolism. Mice were first 
exposed to MNNG (local application into the colon) and, then treated with FLX 
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for 28 days. Although FLX treatment was well tolerated, the body weight of the 
mice treated with FLX was significantly lower (FLX, 21.0 + 1.22 g, n = 5; 
MNNG+FLX, 19.3 + 1.78 g, n = 5; P < 0.001) than in the control groups (CTRL, 
25.6 + 1.78 g, n = 5; MNNG, 23.6 + 0.96 g, n = 5).  
Preneoplastic lesions were evaluated by histopathological analysis, and 
severe MNNG-induced dysplasia was observed in colon sections from mice 
without FLX treatment (Fig. 7A), which was not observed to such a grade in 
those from FLX-treated mice (Fig. 7B).  
 
Figure 7 – Representative histological image of a severely dysplastic area 
(MNNG-exposed mouse). The picture inset (enlarged from the boxed region) 
shows the characteristic severe dysplastic features; e.g., partial loss of cell 
polarity, none goblet cells, presence of Paneth cells (blue arrow), and mitosis 
(white arrows). Pictures were taken at 200x magnification, scale bars represent 
20 m. High-magnification images were taken at 1000x magnification (A). 
Representative image shows a moderate dysplasia (MNNG+FLX treated 
mouse). The inset shows a compressed cryptal luminal opening, elongated 
nuclei (red arrow), a crowded and pseudostrafied area (sectioned black line), 
but with a generally still preserved cell polarity, and a lower number of globet 
cells (yellow arrow). Magnifications are described above (B). 
 
Enumerating dysplastic lesions in MNNG and MNNG+FLX-treated mice 
showed that FLX reduced dysplasia 5.39-fold (Fig. 8A). FLX treatment 
significantly reduced the total values of AC per mm2 7.94-fold (Fig. 8B). 
Microvessels were spread throughout colon stromal areas towards dysplastic 
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areas (Fig. 8C), where FLX treatment was found to decrease vascularization-
related dysplasia 3.13-fold (Fig. 8D).  
 
Figure 8 – ACF-i shown as number of dysplastic lesions per mm2 (A; *P < 0.05 
vs MNNG without FLX, n = 5; FLX+MNNG, n = 4). AC-i shown as number of 
dysplastic single crypts per mm2 (B; *P < 0.05 vs MNNG without FLX, n = 5; 
FLX+MNNG, n = 4). Representative image of a dysplastic area is shown 
(sectioned black line) together with its relative vascularization spreading inside. 
The inset (enlarged from the boxed region) shows two microvessels towards the 
inner region of the dysplastic area. The yellow arrow points to a microvessel 
wall, and the red arrow to erythrocytes inside the microvessel walls. Picture was 
taken at 400x magnification, inset at 1000x magnification, and scale bars 
represent 20 m (C). Relative dysplastic vascularization, shown as the number 
of microvessels per lesion (D; *P < 0.05 vs MNNG without FLX, n = 5; 
FLX+MNNG, n = 4).  
 
4.3.2  Fluoxetine reduces colon proliferation in epithelia and 
stromal areas in methylnitronitrosoguanidine-exposed colon tissue 
Considering the results above, we investigated whether antiproliferative 
effects of FLX could take place in epithelia and stromal areas (Fig. 9A.1 and 
A.2). Labeled sections with anti-Ki67 antibody revealed that FLX attenuated 
(Fig. 9B) the MNNG-induced increase in proliferation at epithelial and stromal 
areas (Fig. 9C and D).  
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Figure 9 – Proliferating cells detected by staining with anti-Ki67 antibody 
(MNNG-treated mouse). (1) Red arrows show dark-brown positive cells 
migrating upward in the epithelial proliferative zone. (2) Stromal positive cells 
are shown by a red arrow near to the cryptal-bottom (A). Proliferating cells (anti-
Ki67 antibody; red arrows) in a MNNG+FLX-treated mouse are shown at the 
cryptal bottom. Pictures were taken at 400x magnification, insets at 1000x 
magnification, and scale bars represent 20 m (B). Proliferation in epithelial 
areas shown by labeling with anti-Ki67 antibody (C; ***P < 0.001 vs MNNG 
without FLX, n = 5; FLX+MNNG, n = 4). Proliferation in colon stromal areas by 
labeling with anti-Ki67 antibody (D; ***P < 0.001 vs MNNG without FLX, n = 5; 
FLX+MNNG, n = 4). 
 
PCNA staining also showed that FLX attenuated the MNNG-induced 
proliferative activity at both colon areas (Fig. 10A and B).  
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Figure 10 – Proliferation in epithelial areas shown by labeling with anti-PCNA  
antibody (A; **P < 0.01 vs MNNG without FLX, n = 4; FLX+MNNG, n = 4). 
Proliferation in colon stromal areas shown by labeling with anti-PCNA antibody 
(B; **P < 0.01 vs MNNG without FLX, n = 4; FLX+MNNG, n = 4). 
 
Moreover, a high c-Myc expression was found at both colonic areas in 
MNNG-treated animals, in which FLX-treatment prevented the increase of 
expression (Fig. 11A and B).  
 
Figure 11 – Expression of c-Myc in epithelia of colon tissue (A; ***P < 0.001 vs 
MNNG without FLX, n = 3; FLX+MNNG, n = 4). Expression of c-Myc in stromal 
areas of colon tissue (B; ***P < 0.001 vs MNNG without FLX, n = 3; 
FLX+MNNG, n = 4). 
 
4.3.1  Fluoxetine modulates the expression of NF-B-signaling 
elements in methylnitronitrosoguanidine-exposed colon tissue 
To understand whether FLX induced effects on colon stromal 
proliferation are associated with a blockade of transcription factor activities, we 
evaluated the expression of NF-B1 (p50) protein in stromal areas (Fig. 12A). 
As shown in Fig. 12B, FLX-treatment, in MNNG-treated mice, significantly 
reduced the nuclear presence of NF-B protein among stromal colonic cells. 
Although cytoplasmic expression of NF-B protein remained unaffected in FLX-
treated mice (Fig. 12C), its cytoplasm-nucleus transitional ratio was decreased 
significantly (Fig. 12D). 
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Figure 12 – Representative histological image of a colonic-longitudinal section 
labeled with anti-NF-B antibody, picture taken at 400x magnification, and scale 
bar of 20 m inserted (A). A cytoplasmic anti-NF-B antibody positively cell 
detected within cryptal area (A.1; 1000x magnification of the boxed region, 
middle-left). (2) Nuclear-NF-B protein detected in stromal cells (A.2; 1000x 
magnification of the boxed region, middle-right). Relative number of nuclear-NF-
B positive cells within colon stromal areas (B; ***P < 0.001 vs MNNG without 
FLX, n = 4; FLX+MNNG, n = 4). Relative number of citoplasmatic-NF-B 
positive cells within PCCS areas (C; P > 0.05). Nuclear-transitional ratio for NF-
B-protein among stromal cells (D; **P < 0.01 vs MNNG without FLX, n = 4; 
FLX+MNNG, n = 4).  
 
To support a presumed FLX-inhibition of the NF-B signaling pathway, 
cytoplasmic expression of NF-B inhibitory proteins was verified within colon 
stromal areas. It was found that FLX significantly increased cytoplasmic IB- 
and IB- expressions in MNNG+FLX-treated mice in comparison with MNNG 
treatment alone (Fig. 13A and B). 
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Figure 13 – Relative number of IB-positive cells (A; *P < 0.05 vs MNNG 
without FLX, n = 4; FLX+MNNG, n = 4), and IB-positive cells within colon 
stromal areas (B; *P < 0.05 vs MNNG without FLX, n = 5; FLX+MNNG, n = 4). 
 
4.3.2  Fluoxetine controls angiogenesis-related markers in 
methylnitronitrosoguanidine-treated mice  
As shown above, FLX treatment might acts against colon preneoplastic 
proliferation and angiogenesis. Angiogenesis is related to stem cell markers and 
takes place within stromal areas. Investigating the potential connection between 
these events, it was observed that FLX treatment decreased the relative 
number of stromal CD133-positive cells in the carcinogen-exposed group 
compared to the MNNG group without FLX (MNNG, 3.73 + 0.44 [n = 4] vs 
MNNG+FLX, 1.97 + 0.14 [n = 4]; P < 0.001). Then, CD133-positive cells 
expressing VEGF were found within stromal areas in mice subjected either to 
MNNG or MNNG+FLX treatments (Figure 14A). However, stromal cells 
expressing VEGF were also decreased in MNNG-exposed animals treated with 
FLX expression (Figure 14B). Intriguingly, CD133 positive cells expressing 
CD34 glycoprotein were only found among MNNG treated mice (Figure 14C) 
while FLX treatment significantly decreased the number of stromal CD34-
positive cells (Figure 14D).  
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Figure 14 – FLX activity and angiogenesis-related markers. (A) Representative 
images of colon sections labeled with anti-CD133 and anti-VEGF antibodies, 
and nuclei stained with DAPI. White arrows indicate single-stained and double-
stained positive cells in stromal areas in colon sections from (A1 to A3) MNNG 
without FLX treatment, and (A4 to A6) MNNG+FLX treatment groups. Pictures 
were taken with FITC (495-521 nm), ultraviolet (358-461 nm), and Texas Red 
(595-605 nm) filters. All pictures were taken at 600x magnification, scale bars 
represent 20 m. (B) Representative images of single stained colon sections 
with anti-VEGF antibody (positive cells are seen with dark-brown cytoplasm) 
from (B1) MNNG without FLX treatment, and (B2) MNNG+FLX treatment 
groups. (B3) Relative number of cells expressing VEGF within colon stromal 
areas (***p<0.001; MNNG without FLX, n = 3; FLX+MNNG, n = 4). All pictures 
were taken at 400x magnification, scale bars represent 50 m. (C) 
Representative images of colon sections labeled with anti-CD133 and anti-
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CD34 antibodies, and nuclei stained with DAPI. White arrows indicate single-
stained and double-stained positive cells in stromal areas in colon sections from 
(C1 to C3) MNNG without FLX treatment, and (C4 to C6) MNNG+FLX treatment 
groups. Pictures were taken as described above. (D) Representative images of 
single stained colon sections with anti-CD34 antibody (positive cells are seen 
with dark-brown cytoplasm) from (D1) MNNG without FLX treatment, and (D2) 
MNNG+FLX treatment groups. (D3) Relative number of CD34 positive cells in 
colon stromal areas (***p<0.001; MNNG without FLX, n = 4; FLX+MNNG, n = 
4). All pictures were taken as described above. 
 
Further, the relative total number of CD31-positive cells was enumerated 
within colon stromal areas, and a significant decrease was found in the MNNG-
exposed group under FLX treatment (MNNG, 3.5 + 0.87 [n = 4] vs MNNG+FLX, 
1.8 + 0.2 [n = 4]; P < 0.01). A comparison between CD34 and CD31-positive 
cells showed a 1.2-fold increase in CD31-positive cell values among MNNG-
exposed mice. 
As known, CD31 is an angiogenesis-related marker, and was enhanced 
during our experiments with MNNG-treatment. Thus, double-staining was 
performed to understand whether CD133 positive cells were expressing CD31 
glycoprotein. In the MNNG and MNNG+FLX groups, CD133 positive cells 
expressed CD31 in microvessel-like structures within stromal areas (Figure 
15A). Potential sites of developing microvessels were detected enumerating 
CD31-positive cell clusters within colon stromal areas (Figure 15B.1 and B.2). 
CD31-positive cell clusters were decreased significantly under FLX-treatment in 
MNNG-exposed mice (Figure 15B.3).  
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Figure 15 – Fluoxetine activity and angiogenesis-related markers. (A) 
Representative images of colon sections labeled with anti-CD133 and anti-
CD31 antibodies, and nuclei stained with DAPI. White arrows indicate single-
stained and double-stained positive cells into stromal areas in colon sections 
from (A1 to A3) MNNG without FLX treatment, and (A4 to A6) MNNG+FLX 
treatment groups. (A3 and A6) Double-stained positive cells are shown by white 
arrows in microvessel-like structures nearby cryptal bottoms. Pictures were 
taken with FITC (495-521 nm), ultraviolet (358-461 nm), and Texas Red (595-
605 nm) filters. All pictures were taken at 600x magnification, scale bars 
represent 20 m. (B) Representative images of single stained colon sections 
with anti-CD31 antibody (positive cells are seen with dark-brown cytoplasm) 
from (B1) MNNG without FLX treatment, and (B2) MNNG+FLX treatment 
groups. Pictures were taken at 400x magnification, scale bars represent 50 m. 
(B3) Relative number of CD31 positive cell clusters detected per colon stroma 
area (**p<0.01; MNNG without FLX, n = 4; FLX+MNNG, n = 4).  
 
4.4 Effects of fluoxetine treatment in colon tumors  
4.4.1 First experiment – Caco-2 cell line  
4.4.1.1 Fluoxetine reduces reactive oxygen species generation 
in Caco-2 cells  
Taking into account that AntiM blocks the mitochondrial complex III 
which leads to increasing ROS production, we tested whether FLX could 
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counteract the AntiM effects. We found that 20 M FLX was able to control 
superoxide (O2
-) generation in Caco-2 adenocarcinoma cells (Fig.16 A and B).  
 
Figure 16 – ROS (O2
-) generation detected by DHE staining and flow cytometry 
in Caco-2 cells after 30 min treatment. A black-arrow shows the combined 
treatment with 10 M AntiM and 20 M FLX (A; spectral colors are light-blue, 
DHE-unstained cells; yellow, DHE stained cells (CTRL); purple, 10 M FLX; 
black, 20 M FLX; red, 10 M AntiM; blue-green, AntiM + 10 M FLX; green, 
AntiM + 20 M FLX). 20 M FLX reduced ROS generation (B; *P < 0.05 and 
***P < 0.001vs 10 M AntiM). 
 
4.4.1.2 Fluoxetine decreases intracellular pH, mitochondrial 
membrane potential, and superoxide generation in hypoxia-exposed 
Caco-2 cells 
Since FLX is a lipophilic weak base, and seems to have potential 
effects on mitochondrial activities, a commercial dye marker was used to 
establish an ipH standard curve for Caco-2 cells by flow cytometry (Fig. 
17A).Then, non-hypoxia (normoxia) and hypoxia-exposed Caco-2 cells were 
treated with 20 M FLX. This FLX treatment slightly decreased ipH under 
standard conditions (1-fold), and significantly in hypoxia-exposed cells (Fig.17B; 
*P < 0.05 vs Hypoxia).  
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Figure 17 – Intracellular pH (ipH) detected by BCEDCF-AM staining and flow 
cytometry in Caco-2 cells (A). Caco-2 cells underwent normoxic or hypoxic 
conditions 24h before treatment with 20 M FLX for 30 min (B; *P < 0.05 vs 
hypoxia). 
 
It is known that ipH interferes in ΔΨm and ROS generation. Treating 
Caco-2 cells with 20 M FLX was found to reduce the ΔΨm 1.5-fold and 1.2-
fold in cultured cells under standard normoxia or hypoxia conditions, 
respectively (Fig. 18A). While hypoxia exposure significantly enhanced ROS 
generation after 24h, the 20 M FLX treatment decreased O2
- production in 
hypoxia-exposed Caco-2 cells (Fig. 18B and C).  
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Figure 18 – Mitochondrial membrane potential (ΔΨm) was detected by JC-1 
staining and flow cytometry. Caco-2 cells underwent normoxia or hypoxia 
conditions, and then were treated with 20 M FLX for 30 min (A; P > 0.05). O2
- 
production detected by DHE staining and flow cytometry in Caco-2 cells after 30 
min treatment. A black-arrow shows 20 M FLX activity in hypoxia-exposed 
Caco-2 cells (B; spectral colors are purple, DHE stained cells (normoxia); light-
blue, 20 M FLX (normoxia); red, hypoxia-exposed cells; green, hypoxia-
exposed cells treated with 20 M FLX). 20 M FLX reduced OS generation (C; 
##P < 0.01 vs normoxia; **P < 0.01 vs hypoxia). 
 
4.4.1.3 Fluoxetine shrinks Caco-2 xenograft-tumors by 
reducing proliferation   
Since there was a clear effect of FLX on the Caco-2 cell line, NOD-
SCID mice bearing Caco-2 xenograft-tumors were treated with FLX for 6 days 
(Fig. 19A). After 6 days treatment, FLX significantly decreased the tumor 
volume (Fig. 19B), and tumor growth rates dropped below zero (Fig. 19C).  
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Figure 19 – NOD-SCID mice bearing Caco-2 xenograft-tumors with or without 
FLX-treatment (A). Tumor volume at day zero (Initial) and sixth day (Final) of 
treatment time (B; *P < 0.05 vs CTRL, n = 5; FLX, n = 5). Relative tumor growth 
during the six days of FLX-treatment (C; **P < 0.01 vs CTRL, n = 3; FLX, n = 4). 
 
To enumerate proliferating tumor cells, a histopathological analysis was 
first performed in tissue sections. In general, tumor tissue showed a 
heterogeneous composition (Fig. 20A) with major areas characterized as TP 
and necrosis (N). A large number of microvessels spread around N areas was 
observed. Then, proliferation was evaluated in the three different main tumor 
areas (IF, PN and TP). Proliferating cells were significantly decreased in mice 
treated with FLX (Fig. 20B to E). Furthermore, this treatment decreased NF-kB1 
protein expression 1.2-fold (Fig. 20F). 
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Figure 20 – Representative image of the four different tumor areas, termed 
invasion front (IF; sectioned red line), tumor parenchyma (TP; sectioned yellow 
line), peri-necrotic area (PN; sectioned white line), and necrosis areas (N; 
sectioned black line). Picture was taken at x40 magnification (A). 
Representative images for IF (B), PN (C), and TP (D) areas in tumor sections 
labeled with anti-Ki67 antibody from CTRL (1) and FLX-treated (2) groups. 
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Pictures were taken at x200 magnification, scale bars represent 50 m. Graph 
shows the proliferative cell values for each tumoral area (E; **P < 0.01 vs 
CTRL, n = 3; FLX, n = 3). Relative expression of NF-kB protein as determined 
by western blot (WB) analysis (F; P > 0.05).  
 
4.4.2 Second experiment – HT29 cell line  
4.4.2.1 Fluoxetine does not induce reactive oxygen species or 
DNA-damage, but delays HT29 cells at the G0/G1 cell-cycle phase  
Next, we sought to understand the effects of FLX on HT29 cells. Cell 
cultures were analyzed for ROS and O2
- generation, and DNA damage. Cells 
exposed to 100 µM FLX showed a 2.5-fold increase in ROS levels after 30min 
treatment, whereas no significant increase was observed with 1 or 10 µM FLX 
(Fig. 21A). Further experiments showed that the ROS amount in cells exposed 
to 100 µM FLX was about 2-fold less after 4h than after 30min treatment (Fig. 
21B). Comparing the O2
- generation between DMSO (solvent control, final 
concentration 1%) and 100 µM FLX exposed cells yielded 2.8-fold increase 
after 30min (Fig. 21C), whereas a 2-fold enhancement was observed for 4h 
(Fig. 21D). Moreover, cells exposed to 100 µM FLX showed a 1.4-fold less O2
- 
production after 4h treatment than after 30min.  
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Figure 21 – Reactive oxygen species (ROS) production analyzed by flow 
cytometry, after exposure to FLX or AntiM for 30min (A; *P < 0.05 vs DMSO), 
and 4h (B; P > 0.05). O2
- production for 30min (C; P > 0.05 vs DMSO), and 4h 
(D; P > 0.05), as detected by DHE staining. DMSO = solvent control (< 1% final 
concentration of DMSO). 
 
 
All FLX concentrations were unable to induce significant DNA damage 
in HT29 cells after 30min or 4h treatments (Fig.22A and B).  
 
Figure 22 – DNA-damage analyzed by comet assay, after exposure to different 
FLX concentrations for 30min (A; *P < 0.05 vs DMSO), and 4h, with % DNA 
content in tail representing DNA-damage (B; *P < 0.05 vs DMSO). H2O2 was 
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applied as positive control. DMSO = solvent control (< 1% final concentration of 
DMSO). 
 
A viability and apoptosis test was performed by flow cytometry in HT29 
cells exposed to different FLX concentrations. After 24h, 100 µM FLX 
decreased cell viability significantly and induced apoptosis, although 1 and 10 
µM were unable to promote similar effects (Figure 23).  
 
Figure 23 – Viability and apoptosis assay (Annexin V/ PI) performed by flow 
cytometry, after exposure to different FLX concentrations for 24h (*P<0.05 vs 
DMSO). DMSO = solvent control (< 1% final concentration of DMSO). DMSO = 
solvent control (< 1% final concentration of DMSO). 
 
 
We further investigated whether FLX could act upon the cell-cycle of 
colon tumor cells. 10 µM FLX caused a significant delay of cells in G0/G1 phase 
after 24h treatment, and a 5.5-fold decrease in G2-M phase (Fig. 24A). When 
the cell cycle progression related protein p27 was investigated, 10 µM FLX 
caused a slight upregulation of its expression, while 20 µM FLX increased it 1.3-
fold (Fig. 24B). 
61 
 
 
Figure 24 – Distribution of HT29 cells in the cell-cycle phase analyzed by flow 
cytometry (A) and expression of the cell-cycle related protein p27 (B). In (A), the 
percentage of cells is shown in G0/G1, S, and G2/M phases are shown, analyzed 
from cultures with or without a 24h FLX treatment (A; **P < 0.01 vs DMSO). In 
(B), the relative expression of p27 protein in HT29 cells, determined by Western 
Blot analysis is displayed (B; P > 0.05).  
 
4.4.2.2 Fluoxetine reduces reactive oxygen species generation 
in HT29 cells  
Having the results from Caco-2 cells in mind, we tested whether FLX 
could act against AntiM activity in HT29 cells. Once more 20 M FLX 
significantly reduced the O2
- generation induced by AntiM in colon tumor cells 
(Fig. 25A and B). 
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Figure 25 – O2
- production detected by DHE staining and flow cytometry in 
Caco-2 cells after 30 min treatment. A black-arrow shows combined treatment 
with 10 M AntiM and 20 M FLX (A; spectral colors are extra-light-blue, DHE-
unstained cells; light-blue, DHE stained cells (CTRL); yellow, 10 M FLX; 
purple, 20 M FLX; red, 10 M AntiM; blue-green, AntiM + 10 M FLX; green, 
AntiM + 20 M FLX). 20 M FLX reduced AntiM dependent ROS generation (B; 
*P < 0.05 and ***P < 0.001vs 10 M AntiM). 
 
4.4.2.3 Fluoxetine decreases intracellular pH, membrane 
mitochondrial potential, and superoxide generation arresting hypoxia-
exposed HT29 cells at the G0/G1 cell-cycle phase  
As found in Caco-2 cells, 20 M FLX also decreased ipH in hypoxia-
exposed HT29 cells (Fig. 26A and B; *P < 0.05 vs hypoxia). 
 
Figure 26 – A standard curve for ipH determined by BCEDCF-AM staining and 
flow cytometry in HT29 cells (A). HT29 cells underwent normoxic or hypoxic 
conditions 24h before treatment with 20 M FLX for 30 min (B; *P < 0.05 vs 
hypoxia). 
 
In addition, 20 M FLX treatment significantly decreased ΔΨm in 
hypoxia-exposed HT29 cells (Fig.27A). Under the same experimental 
conditions, FLX treatment significantly reduced the O2
- generation (Fig. 27B). 
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Figure 27 – The mitochondrial membrane potential (ΔΨm) was analyzed in 
non-hypoxia exposed (normoxia) and hypoxia-exposed HT29 cells. Cell cultures 
were treated with 20 M FLX for 30 min (A; *P < 0.05 vs hypoxia). O2
- 
production was detected by DHE staining and flow cytometry in Caco-2 cells 
after 30 min treatment. A black-arrow shows the activity of 20 M FLX in 
hypoxia-exposed Caco-2 cells (B; spectral colors are purple, DHE stained cells 
(normoxia); light-blue, 20 M FLX (normoxia); red, hypoxia-exposed cells; 
green, hypoxia-exposed cells treated with 20 M FLX). 20 M FLX reduced 
ROS generation (C; ##P < 0.01 vs normoxia; **P < 0.01 vs hypoxia). 
 
Then, cell-cycle phases were analyzed in non-hypoxia and hypoxia-
exposed HT29 cells treated with 20 M FLX for 24h. FLX induced a G0/G1 cell-
cycle arrest in HT29 cells under both of two applied experimental conditions, 
meaning a significant increase of cells in G1-phase, as well as a suppression of 
S-phase (Fig.28A and B).  
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Figure 28 – Flow cytometric cell-cycle analysis in HT29 cells. HT29 cells 
underwent normoxia or hypoxia 24h before treatment with DMSO (1%) or 20 
M FLX for another 24h. Percentages of normoxic (A) and hypoxic HT29 (B) 
cells are shown per cell-cycle phase with or without FLX treatment for 24 h (***P 
< 0.001 vs DMSO). 
 
 While 20 M FLX treatments had just slight effects upon p27 protein 
expression under standard-cell culture conditions after 24h, FLX enhanced its 
expression in hypoxia-exposed cells 1.3-fold (Fig. 29A and B). However, FLX 
treatment did not affect the protein expression of cyclin E (Fig. 29A and C).  
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Figure 29 – Western Blot analysis of the expression of p27 and cyclin E. 
Representative image of a western blot analysis for p27 and cyclin E proteins. 
The β-actin expression was considered as endogenous control (A). 
Quantification of the relative expression of p27 (B) and cyclin E (C) proteins in 
HT29 cells (P > 0.05).  
   
4.4.2.4 Fluoxetine shrinks HT29 xenograft-tumors by reducing 
proliferation   
To verify the effects of FLX in another colon tumor model, NOD/SCID 
mice bearing HT29 xenograft-tumors were treated with the antidepressant for 
three days. The body weight of the mice remained unchanged until the end of 
this treatment (CTRL, 15.4 + 2 g, n = 5; FLX, 14.4 + 2.5 g, n = 6). FLX treatment 
significantly decreased the tumor volume (Fig. 30A), yielding RTG values below 
zero (Fig. 30B), and reduced tumor weight (2.2-fold) in comparison with the 
non-treated group (Fig. 30C).  
Figure 30 – Tumor volume on the first (Initial) and fourth day (Final) (A; *P < 
0.05 vs CTRL, n = 5; FLX, n = 5). Relative tumor growth during the experiment 
(B; **P < 0.01 vs CTRL, n = 5; FLX, n = 5). Tumor weight at the end (fourth day) 
after the three days FLX-treatment (C; P > 0.05; CTRL, n = 5; FLX, n = 5). 
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Proliferation was then evaluated in three different tumor areas (Fig. 
31A). In control tumors, proliferation within IF (Fig. 31B.1) and PN (Fig. 31C.1) 
was found to be significantly higher than in TP areas (Fig. 31D.1; IF, 17.03 + 
3.38; PN, 13.92 + 3.383; TP, 7.9 + 2.34; P < 0.01 vs TP). FLX-treatment 
reduced proliferation in IF (Fig. 31B.2) and PN (Fig. 31C.2) areas significantly in 
comparison with the control samples, whereas proliferative rates in TP (Fig. 
31D.2) areas remained unchanged (Fig. 31E).  
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Figure 31 – Representative image indicating the locations of four different 
tumor areas, termed invasion front (sectioned red line), tumor parenchyma 
(sectioned yellow line), peri-necrotic area (sectioned white line), and necrotic 
area (N; sectioned black line). The picture was taken at x100 magnification (A). 
Representative images for IF (B), PN (C), and TP (D) areas in tumor sections 
labeled with anti-Ki67 antibody from CTRL (1) and FLX-treated (2) groups. 
Pictures were taken at 400x magnification, scale bars represent 20 m. Graph 
shows the proliferative cell values for each tumoral area (E; **P < 0.01 vs 
CTRL, n = 4; FLX, n = 5).  Gene expression for cyclin D1, BIRC5, and NF-kB1 
was quantified by qRT=PCR (F; *P < 0.05 vs CTRL; n = 3 [cyclin D1] and 5 
[BIRC5] per group).  
 
4.4.3 Third experiment – HT29 tumors   
4.4.3.1 Fluoxetine and 5-fluorouracil have similar effects 
against HT29 xenograft-tumors   
We next aimed to examine whether the FLX induced effects are 
comparable with those of the known chemotherapeutic agent 5-fluoracil (5-FU). 
Again, FLX-treatment reduced RTG values to below zero (Fig. 32A). 5-FU also 
yielded a reduced tumor growth, although not as efficiently as FLX. However, 
the reduction of the tumor weight compared to the control was similar in both 
treatments (Fig. 32B).  
 
Figure 32 – Tumor growth between the first and fourth days of FLX-treatment 
(A; *P < 0.05 vs CTRL). Tumor weight at the end (fourth day) after the three 
days FLX-treatment (B; *P < 0.05 vs CTRL). 
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4.4.3.1 Fluoxetine acts against tumor metabolism and 
molecular signaling 
Using a Luminex-based technology, protein expression of mitochondrial 
complexes was quantified in tumor samples. FLX had no effect on complex I 
and IV expression, while 5-FU decreased the amounts of both protein almost 
1.3-fold. FLX and 5-FU respectively enhanced complex II amount 1.4-fold and 
2.2-fold. Moreover, FLX reduced the expression of complex III 1.4-fold and 
complex V (ATPase) 1.6-fold (Fig. 33A). FLX treatment also decreased a 
marker of mitochondrial activity (TOMM20) 1.4-fold (Fig. 33B). 
 
Figure 33 – Tumor lysates were analyzed with a human OXPHOS kit. Median 
fluorescence intensity (MFI) was acquired with a Luminex® system (A; P > 
0.05). Gene expression of TOMM20 was analyzed by RT-PCR (B; P > 0.05) 
 
FLX and 5-FU treatments enhanced the glucose serum levels in 
NOD/SCID mice bearing HT29 xenograft-tumors 1.5-fold and 1.8-fold, 
respectively. This was accompanied by a significant increase in serum lactate 
levels, whereas no metabolic changes were observed (Fig. 34A). However, 5-
FU treatment induced a significant tumor glucose level increase, which FLX 
enhanced 2.6-fold. Also, FLX and 5-FU increased the tumor lactate levels 1.9-
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fold and 1.6-fold, respectively. Calculating the metabolic activity showed that 5-
FU significantly enhanced tumor glycolysis [Fig. 34B; CTRL vs FLX (1.42-fold) 
and 5-FU (2.4-fold)]. Additionally, FLX reduced the gene expression of the 
glucose transporter (GLUT1) and lactate dehydrogenase (LDHA) 1.3-fold, while 
the lactate transporter (MCT-4) was significantly downregulated (Fig. 34C).  
 
 
Figure 34 – Glycolytic patterns analyzed in serum samples (A) and tumor 
lysates (B) with biochemical methods (B; *P < 0.05 and **P 0.01 vs CTRL). 
Gene expression of Glut1, MCT4 and LDHA analyzed by RT-PCR (C; P < 0.05 
vs CTRL). 
 
FLX and 5-FU treatments downregulated NOX-1 mRNA expression 1.2-fold 
and 1.9-fold, respectively. While 5-FU enhanced HIF-1 mRNA expression, FLX-
treatment downregulated its mRNA expression 2-fold (Fig. 35A). Moreover, FLX 
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decreased all phosphorylated-proteins from the Akt-mTOR signaling pathway around 
1.1-fold (Fig. 35B).  
 
Figure 34 – Gene expression of NOX-1 and HIF-1 as analyzed by RT-PCR (A; 
P > 0.05). Tumor lysates (300µg/mL) were analyzed with the Akt/mTOR 
Phosphoprotein Magnetic Bead Kit according to the assay protocol. MFI was 
measured with a Luminex® system (B; P > 0.05). 
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5 Discussion 
5.1 Standard-fluoxetine doses show safety in toxicological in 
vitro tests  
It should first be considered that FLX showed no antioxidant potential in 
a cell-free assay, as well as it did not induce any pro-oxidant or DNA-damaging 
events in our cell culture models. Therefore, FLX does not seem to alter non-
malignant cellular functions under standard-cell culture conditions to a relevant 
degree. It was previously reported that normal peripheral blood mononuclear 
and tonsilar B cells remained highly viable after treatments with 5, 10 or 20µM 
FLX for 24h, whereas these same drug concentrations induced DNA-
fragmentation, loss of ΔΨm, and apoptosis in Burkitt lymphoma cells [17]. 
Furthermore, experiments with normal rats subjected to FLX-treatment have 
shown that it protects brain tissue against stress-related damage, mainly up-
regulating antioxidant capacity [9-11,81].  
Djordjevic and colleagues have analyzed liver tissue from stressed and 
non-stressed rats and found that FLX just modulated antioxidant mechanisms in 
those subjected to stressful conditions. They also found that FLX did not 
prevent DNA fragmentation or apoptosis in stressed rats [82]. Data from spleen 
samples of mice injected and non-injected with B16F10 melanoma cells showed 
that FLX reversed pro-oxidant effects of melanoma tumors [14].  
On the other hand, FLX promoted DNA fragmentation and apoptosis 
throughout oxidative stress and mitochondrial-related damage dysfunction in 
human Burkitt lymphoma and ovarian cancer cells, [16-18]. Furthermore, 
treating rat PC12, C6 glioma and human SH-SY5Y neuroblastoma cells with 
FLX was shown to increase DNA-damage, oxidative stress, and mitochondrial 
72 
 
dysfunction reducing cell viability and growth [83-84]. Analyzing blood 
peripheral cells from stressed mice [12] and brain tissue from tumor-bearing 
mice [13] further supported the notion that FLX has a pro-oxidant-related activity 
[12-13], 
Taken together, this shows that FLX has a safe standard activity upon 
fibroblast cell cultures, while divergences about its effects arise due to different 
experimental designs and conditions.  
5.2 Fluoxetine reduces colon dysplasia taking preneoplastic 
angiogenesis under control   
Although FLX showed no antioxidant, pro-oxidant or DNA-damaging 
potential, previous reports have shown that it might control preneoplastic 
lesions [5,20]. Our current data support the idea that FLX acts as a 
chemopreventive agent reducing preneoplastic lesions in the colon. From our 
first model, we can infer that FLX might have a chemopreventive potential 
against dysplasia, since treatment was started before the carcinogen 
application. The second model reinforces this idea of reduction of that 
carcinogen-related dysplasia, adding the information that FLX could reduce pre-
existent colon preneoplastic lesions. Considering the differences between our 
carcinogenic models together with the similarities found in both of them, it 
almost ensures that FLX takes the carcinogen-induced preneoplastic changes 
under control by reducing epithelia proliferation. Thus, proliferation is the first 
step from where FLX might act in decreasing colon dysplasia.   
Previous reports have shown that mutated cells, after DMH or MNNG 
treatments, can acquire a high proliferation capacity [46,55,85-89]. Treating rats 
with DMH and FLX, Tutton and Barkla first found that FLX reduces colon cryptal 
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proliferation [20]. Koh et al used a DMH-metabolite (Azoxymethane), in 
association with oral treatment of dextran sulfate sodium, to induce colitis-
associated colon cancer in mice. They found that FLX does not induce colon 
apoptosis, while decreasing colon dysplasia and tumors [5]. Besides, 
chemoprevention against the MNNG-induced colon dysplasia was observed in 
association with decreased proliferation and c-Myc expression [87,90].  
Interestingly, FLX reduced dysplasia and preneoplastic angiogenesis in 
both carcinogenic models. From the dataset of the MNNG-induced dysplasia 
model, we observed that the effects of FLX in reducing preneoplastic 
angiogenesis were directly related to the decrease of stromal proliferation. Our 
data further suggest that, by suppressing NF-B nuclear expression due to 
increased expression of cytoplasmic IB- and IB-proteins, FLX reduced c-
Myc expression and then stromal proliferation. In fact, FLX has been shown to 
inhibit NF-B signaling in epithelial carcinogen-induced  high cell proliferation 
[5]. Moreover, high NF-B-transcriptional activity was closely associated with 
the transformation from normal to reactive stroma phenotype, since NF-B 
promotes the expression of pro-inflammatory molecules and increases the 
number of periendothelial cells [61-62]. Indeed, inhibiting the proliferation of 
colon cancer cells has been achieved by suppressing NF-B-transcriptional 
activity in vitro and in vivo, which reduces the expression of its downstream 
genes, such as c-Myc and VEGF [91-92].  
The present findings also reveal that FLX might reduce VEGF 
expression within the stromal compartment of the colon tissue. This ties the 
results regarding preneoplastic angiogenesis and stromal proliferation together. 
However, it should be considered that the activity of FLX on VEGF expression 
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is a controversial issue, and no study has been published about the relationship 
between FLX, colon carcinogenesis, and angiogenesis to this day. Concerning 
VEGF, FLX treatment has been shown to reduce the expression in lung under 
pathological conditions [93-95]. On the other hand, the effects of FLX on VEGF 
levels in brain tissue provoke further discussion [96], since there was a large 
difference between what has been observed in vivo and in vitro [97-100] in 
comparison with human studies [96,101]. Altogether, VEGF expression has 
been known to promote angiogenesis and proliferation [102-103], and it has 
been acknowledged that proliferation plays a key role during angiogenesis 
[103].   
In the MNNG-induced dysplasia model, we further found that FLX might 
decrease angiogenesis-related cell markers. It encloses the question whether 
FLX treatment could directly act upon angiogenesis-related cell phenotypes. 
These current data support the hypothesis that the anti-angiogenic potential of 
FLX could be related to the control of angiogenesis-related stem cell markers in 
colon preneoplastic lesions. Intriguingly, this hypothesis was abetted by the 
discovery of a small subset of stromal spindle cells expressing CD133 and 
CD34 in angiofibromas. That report suggested that tumors promote stromal 
cells to transit toward an endothelial phenotype [104]. Other studies reinforced 
this hypothesis, since endothelial progenitor cells lose the expression of CD133 
during their differentiation process into vascular cells, while the expression of 
CD34 is increased [105-107]. This process has also been related to high 
proliferation [103], which might mean a downregulation of CD34 expression 
upon further differentiation [108]. In addition, CD31-positive cells have been 
designated as a mature endothelial lineage promoting microvessels [109]. 
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Hence, vascular smooth muscle cells increased the expression of CD31 during 
their differentiation process, whereas a simultaneous decrease of CD133 and 
CD34 progenitor markers was observed [110].  
Taken together, our current data lead to the idea that FLX effectively 
acts against colon preneoplastic lesions. FLX seems to have a broad and 
complex activity on epithelia and stromal areas; its anti-angiogenic effect might 
be the key point for clarification of its activity against carcinogen-induced 
dysplasia in colon tissue. 
5.3 Fluoxetine takes tumor metabolism under control to reduce 
its growth  
Having the data from Caco-2 and HT29 cells in mind, we can observe 
that FLX reduced ROS production to take control upon tumor proliferation and 
growth. It is well known that ROS promote tumor growth [71,111]. However, 
ATP depletion should be also considered as another mechanism driving cancer 
cells to death [112].  Because FLX is a lipophilic weak base [2] it quickly 
diffuses into multiple body-sites [113]. Another lipophilic weak base (AU-1421) 
was reported to uncouple mitochondrial oxidative phosphorylation dissipating 
the proton motive force during the energized state, which inhibited ATP 
synthesis [114]. It is known that lipophilic weak bases, such as FLX, show high 
resonance energy delocalizing positive charges in their protonated form, which 
reduces mitochondrial respiratory rate and ATP synthesis [114-116]. Thus, a 
connection between our current findings becomes clear considering that ipH is 
modulated or can modulate proton currents in cells; besides, these events are 
close connected with the homeostasis in mitochondrial energy generation 
machinery and, then, cell proliferation [114-115,117]. 
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From our in vitro and in vivo data, it is reasonable to conclude that FLX 
deconstructs the tumoral cellular energy generation machinery, arresting tumor 
cells in G0/G1 cell-cycle phase without a DNA-damaging activity. Reviewing the 
chemical properties of FLX [2,113] together with previous hypotheses regarding 
the relationship between lipophilic weak acids and ipH [115,118-119], it sounds 
reasonable that a non-ionized FLX form passively diffuses across the cell 
membrane, becomes trapped and accumulates within acidic cellular 
compartments. Taking into account that the main function of voltage-gated 
proton channels is to extrude acid from cells FLX was shown to inhibit those 
[115]; also, it blocked the mitochondrial respiratory chain [116]. This might 
reinforce the idea that FLX-induced ipH acidification reduces the tumoral 
strategy of hyperpolarizing ΔΨm as a way to maintain the aerobic glycolysis.  
Harguindey et al suggested that tumors have alkaline ipH and acidic 
microenvironment due to acid-base disturbances that completely differentiate 
them from normal tissues [120]. Specifically, glycolysis increases hydrogen ions 
enhancing the ΔΨm, which allows pyruvate to reenter the redox matrix inducing 
OXPHOS [76,120]. Activating MCT4 transporters, tumors are not only able to 
keep their aerobic glycolytic metabolism functional, but also to alkalinize ipH 
excreting the excessive amount of lactate and hydrogen ions [69-70,72,76]. It 
was further observed that hypoxic cells increase, in order to gain ATP 
production, their hypoxia-related aerobic glycolysis through ipH-associated 
strategies resulting in an uncontrolled cell growth, which in turn enhances the 
development of new hypoxia microenvironments [71,76,111,121].  
The findings of FLX enhancing expression of the cell-cycle checkpoint 
related protein p27 and the observed G0/G1 cell-cycle arrest in hypoxia-exposed 
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cells uphold our hypothesis. Currently, a growing body of evidences [7,122-123] 
supports the first description of FLX inhibiting colon tumor proliferation [20]. 
Furthermore, FLX has been shown to directly bind to the DNA via groove mode 
and high attraction force [124]. This may further enhance FLX induced delays in 
cell-cycle progression by inhibiting DNA synthesis [22,125-128]. In breast 
tumors, FLX was shown to arrest cells at G0/G1 phase by disrupting skp2-
CKS1 assembly, which is required to enable cell cycle progression [129]. 
Recent data have support the idea that FLX acts against tumor proliferating 
cells reducing c-Myc and cyclins (D1, D3, E, B, and A), whereas cell-cycle 
checkpoints (p15, p16, p21, p27, and p53) are enhanced [7,122,129].  
Our current data show that FLX effects are comparable with those of 
the well established chemotherapeutic agent 5-FU during a short-time 
treatment. It nevertheless suggests that the mechanism of action differed 
between both agents, with FLX treatment modulating tumor metabolism and 
thereby reducing transcription factors and tumor growth. While there is no 
literature data available comparing the effects of FLX with 5-FU, it is known that 
FLX prolongs the drug-circulation time and activity of some chemotherapeutic 
agents reducing multidrug resistance [27-28,130-131]. Besides, it is well known 
that taking tumor metabolism under control modulates cell signaling mediators 
and pathways, such as HIF-1 and Akt/mTOR [69-70,72,132]. Up to day, the 
literature lacks in reports about the ability of FLX to modulate HIF-1 and Akt 
signaling in tumors. Data from brain and pulmonary tissues have shown that 
FLX counteracts hypoxia-induced damage, reducing HIF-1 expression and 
activity [94,133-134]. FLX was also found to reduce monocrotaline-induced 
pulmonary arterial remodeling by lowering Akt phosphorylation [135]. However, 
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most of findings regarding the relationship between FLX and Akt signaling were 
produced in brain tissue, and argue that FLX enhances Akt/PI3K signaling 
pathway [136-139]. Nevertheless, FLX was shown to have different effects upon 
normal, stress-exposed, and malignant cells [17,82]. Besides, the large 
difference between normal and tumor tissues supports, by itself, the contrasting 
FLX mediated effects on Akt signaling, and suggest that FLX activity might 
decrease this signaling pathway during colon tumor shrinkage.    
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6 Conclusion 
Our collective data suggest that FLX is a remarkable chemopreventive 
and oncostatic agent against colon preneoplastic lesions and tumors, acting 
without DNA-damage or ROS generation. The current findings suggest that FLX 
might control colon dysplasia, seen for example as reduction of angiogenesis, 
by its activity on preneoplasia-related reactive colon stroma. Moreover, FLX 
seems to take the malignant metabolism under control, which contributes to the 
reduction of the colon tumors. These effects of FLX may lead to new insights 
into tumor therapy, where depleting energy generation becomes a reasonable 
strategy to shrink colon tumors.      
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